

# Antonella Giannantoni Ag

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/698700/publications.pdf>

Version: 2024-02-01

55  
papers

1,966  
citations

377584

21  
h-index

274796

44  
g-index

55  
all docs

55  
docs citations

55  
times ranked

1605  
citing authors

#	ARTICLE	IF	CITATIONS
1	Regarding the diagnosis of detrusor underactivity in: "Urodynamics criteria of detrusor underactivity in women underwent middle urethral sling for stress urinary incontinence: What is the clinical role? <i>Neurourol Urodyn</i> 2021. August 22. doi.org/10.1002/nau.24773" <i>Neurourology and Urodynamics</i> , 2022, 41, 508-509.	0.8	0
2	IncobotulinumtoxinA versus onabotulinumtoxinA intradetrusor injections in patients with neurogenic detrusor overactivity incontinence: a double-blind, randomized, non-inferiority trial. <i>Minerva Urology and Nephrology</i> , 2022, 74, .	1.3	2
3	Can urethral re-bulking improve the outcomes of a prior urethral bulking?. <i>Therapeutic Advances in Urology</i> , 2022, 14, 175628722110692.	0.9	1
4	The International Female Coital Incontinence Questionnaire (IFCI-Q): Development, Validation and Reliability Study. <i>Journal of Sexual Medicine</i> , 2022, 19, 158-163.	0.3	3
5	Urethral Bulking in the Treatment of Stress and Mixed Female Urinary Incontinence: Results from a Multicenter Cohort and Predictors of Clinical Outcomes. <i>Journal of Clinical Medicine</i> , 2022, 11, 1569.	1.0	5
6	Efficacy and Safety of AbobotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity Incontinence Performing Regular Clean Intermittent Catheterization: Pooled Results from Two Phase 3 Randomized Studies (CONTENT1 and CONTENT2). <i>European Urology</i> , 2022, 82, 223-232.	0.9	17
7	Increased risk of transurethral and suprapubic catheter self-extraction in COVID-19 patients: real-life experience. <i>British Journal of Nursing</i> , 2022, 31, S24-S30.	0.3	0
8	The Prognostic Value of the Circulating Tumor Cell-Based Four mRNA Scoring System: A New Non-Invasive Setting for the Management of Bladder Cancer. <i>Cancers</i> , 2022, 14, 3118.	1.7	2
9	AUTHOR REPLY. <i>Urology</i> , 2021, 148, 46.	0.5	0
10	Continuing care for patients affected by urologic chronic pelvic pain in the era of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic. <i>Neurourology and Urodynamics</i> , 2021, 40, 397-403.	0.8	5
11	The Role of Emotional Condition in Patients With Lower Urinary Tract Symptoms Performing Uroflowmetry. <i>Urology</i> , 2021, 148, 37-46.	0.5	3
12	Long-Lasting Palliation of Bone Oligometastatic Prostate Cancer After Repeated Stereotactic Body Radiotherapy. <i>Ochsner Journal</i> , 2021, 21, 301-305.	0.5	0
13	Resilience in the face of pelvic pain: A pilot study in males and females affected by urologic chronic pelvic pain. <i>Neurourology and Urodynamics</i> , 2021, 40, 1011-1020.	0.8	5
14	Urodynamics criteria of detrusor underactivity in women underwent middle urethral sling for stress urinary incontinence: What is the clinical role?. <i>Neurourology and Urodynamics</i> , 2021, 40, 1955-1965.	0.8	3
15	Correlation between High PD-L1 and EMT/Invasive Genes Expression and Reduced Recurrence-Free Survival in Blood-Circulating Tumor Cells from Patients with Non-Muscle-Invasive Bladder Cancer. <i>Cancers</i> , 2021, 13, 5989.	1.7	11
16	Nocturnal polyuria in men performing uroflowmetry for lower urinary tract symptoms. <i>Archivio Italiano Di Urologia Andrologia</i> , 2021, 93, 445-449.	0.4	1
17	Nocturia and Nocturnal Polyuria in Neurological Patients: From Epidemiology to Treatment. A Systematic Review of the Literature. <i>European Urology Focus</i> , 2020, 6, 922-934.	1.6	16
18	Triage of functional, female and neuro-urology patients during and immediately after the Covid-19 outbreak. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2020, 72, 513-515.	3.9	6

#	ARTICLE	IF	CITATIONS
19	Bladder and bowel dysfunction, adaptive behaviour and psychiatric profiles in adults affected by autism spectrum disorders. <i>Neurourology and Urodynamics</i> , 2019, 38, 1866-1873.	0.8	6
20	Botulinum Neurotoxin A Intravesical Injections in Interstitial Cystitis/Bladder Painful Syndrome: A Systematic Review with Meta-Analysis. <i>Toxins</i> , 2019, 11, 510.	1.5	17
21	The impact of Mirabegron on sexual function in women with idiopathic overactive bladder. <i>BMC Urology</i> , 2019, 19, 7.	0.6	7
22	Urodynamic findings and functional outcomes after laparoscopic sacrocolpopexy for symptomatic pelvic organ prolapse. <i>International Urogynecology Journal</i> , 2019, 30, 589-594.	0.7	12
23	Feasibility of mirabegron in the treatment of overactive bladder in patients affected by Parkinson's disease: A pilot study. <i>Therapeutic Advances in Neurological Disorders</i> , 2019, 12, 175628641984345.	1.5	16
24	<i>Serenoa repens</i> + selenium + lycopene vs tadalafil 5 mg for the treatment of lower urinary tract symptoms secondary to benign prostatic obstruction: a Phase IV, non-inferiority, open-label, clinical study (SPRITE study). <i>BJU International</i> , 2018, 122, 317-325.	1.3	10
25	Adolescence transitional care in neurogenic detrusor overactivity and the use of OnabotulinumtoxinA: A clinical algorithm from an Italian consensus statement. <i>Neurourology and Urodynamics</i> , 2018, 37, 904-915.	0.8	6
26	A practical approach to the management of nocturia. <i>International Journal of Clinical Practice</i> , 2017, 71, e13027.	0.8	76
27	Association between selenium and lycopene supplementation and incidence of prostate cancer: Results from the post-hoc analysis of the procomb trial. <i>Phytomedicine</i> , 2017, 34, 1-5.	2.3	26
28	Long-term efficacy of the trans-obturator and retropubic mid-urethral slings for stress urinary incontinence: update from a randomized clinical trial. <i>World Journal of Urology</i> , 2016, 34, 585-593.	1.2	43
29	Chronic prostatitis: how to give our best without apposite vagueness. <i>BJU International</i> , 2015, 116, 499-500.	1.3	2
30	OnabotulinumtoxinA Intravesical Treatment in Patients Affected by Overactive Bladder Syndrome: Best Practice in Real-Life Management. <i>Urologia</i> , 2015, 82, 179-183.	0.3	10
31	Intradetrusorial Botulinum Toxin in Patients with Multiple Sclerosis: A Neurophysiological Study. <i>Toxins</i> , 2015, 7, 3424-3435.	1.5	5
32	OnabotulinumtoxinA intradetrusorial injections improve sexual function in female patients affected by multiple sclerosis: preliminary results. <i>World Journal of Urology</i> , 2015, 33, 2095-2101.	1.2	23
33	Is intravesical BCG alone still the only truly effective intravesical therapy for high risk non-muscle invasive bladder cancer?. <i>Journal of Clinical Oncology</i> , 2015, 33, e15544-e15544.	0.8	0
34	Urodynamic Evaluation after High-Intensity Focused Ultrasound for Patients with Prostate Cancer. <i>Prostate Cancer</i> , 2014, 2014, 1-7.	0.4	6
35	An Updated Systematic Review and Statistical Comparison of Standardised Mean Outcomes for the Use of Botulinum Toxin in the Management of Lower Urinary Tract Disorders. <i>European Urology</i> , 2014, 65, 981-990.	0.9	148
36	Resiniferatoxin induces death of bladder cancer cells associated with mitochondrial dysfunction and reduces tumor growth in a xenograft mouse model. <i>Chemico-Biological Interactions</i> , 2014, 224, 128-135.	1.7	12

#	ARTICLE	IF	CITATIONS
37	The Efficacy and Safety of Duloxetine in a Multidrug Regimen for Chronic Prostatitis/Chronic Pelvic Pain Syndrome. <i>Urology</i> , 2014, 83, 400-405.	0.5	30
38	Onabotulinumtoxin-A intradetrusorial injections modulate bladder expression of NGF, TrkA, p75 and TRPV1 in patients with detrusor overactivity. <i>Pharmacological Research</i> , 2013, 68, 118-124.	3.1	29
39	Contemporary Management of the Painful Bladder: A Systematic Review. <i>European Urology</i> , 2012, 61, 29-53.	0.9	104
40	Urologic Dysfunction and Neurologic Outcome in Coma Survivors After Severe Traumatic Brain Injury in the Postacute and Chronic Phase. <i>Archives of Physical Medicine and Rehabilitation</i> , 2011, 92, 1134-1138.	0.5	28
41	Botulinum Toxin Type A in Patients With Parkinson's Disease and Refractory Overactive Bladder. <i>Journal of Urology</i> , 2011, 186, 960-964.	0.2	98
42	Two -Year Efficacy and Safety of Botulinum a Toxin Intravesical Injections in Patients Affected by Refractory Painful Bladder Syndrome. <i>Current Drug Delivery</i> , 2010, 7, 1-4.	0.8	33
43	Botulinum A Toxin Intravesical Injections for Painful Bladder Syndrome: Impact Upon Pain, Psychological Functioning and Quality of Life. <i>Current Drug Delivery</i> , 2010, 7, 442-446.	0.8	33
44	Six-Year Follow-Up of Botulinum Toxin A Intradetrusorial Injections in Patients with Refractory Neurogenic Detrusor Overactivity: Clinical and Urodynamic Results. <i>European Urology</i> , 2009, 55, 705-712.	0.9	132
45	Botulinum Toxin A for Overactive Bladder and Detrusor Muscle Overactivity in Patients With Parkinson's Disease and Multiple System Atrophy. <i>Journal of Urology</i> , 2009, 182, 1453-1457.	0.2	124
46	Botulinum A toxin in the treatment of neurogenic detrusor overactivity: a consolidated field of application. <i>BJU International</i> , 2008, 102, 2-6.	1.3	15
47	Bladder and Urethral Sphincter Function after Radical Retropubic Prostatectomy: A Prospective Long-Term Study. <i>European Urology</i> , 2008, 54, 657-664.	0.9	82
48	Botulinum A Toxin Intravesical Injection in Patients With Painful Bladder Syndrome: 1-Year Followup. <i>Journal of Urology</i> , 2008, 179, 1031-1034.	0.2	137
49	Botulinum-A Toxin Injections Into the Detrusor Muscle Decrease Nerve Growth Factor Bladder Tissue Levels in Patients With Neurogenic Detrusor Overactivity. <i>Journal of Urology</i> , 2006, 175, 2341-2344.	0.2	139
50	Botulinum A Toxin Intravesical Injections in the Treatment of Painful Bladder Syndrome: A Pilot Study. <i>European Urology</i> , 2006, 49, 704-709.	0.9	120
51	New Frontiers in Intravesical Therapies and Drug Delivery. <i>European Urology</i> , 2006, 50, 1183-1193.	0.9	101
52	ASSESSMENT OF BLADDER AND URETHRAL SPHINCTER FUNCTION BEFORE AND AFTER RADICAL RETROPUBIC PROSTATECTOMY. <i>Journal of Urology</i> , 2004, 171, 1563-1566.	0.2	78
53	INTRAVESICAL RESINIFERATOXIN VERSUS BOTULINUM-A TOXIN INJECTIONS FOR NEUROGENIC DETRUSOR OVERACTIVITY: A PROSPECTIVE RANDOMIZED STUDY. <i>Journal of Urology</i> , 2004, 172, 240-243.	0.2	140
54	Pelvic Floor Muscle Behavior During Valsalva Leak Point Pressure Measurement in Males and Females Affected by Stress Urinary Incontinence. <i>Journal of Urology</i> , 2003, 170, 485-489.	0.2	17

#	ARTICLE	IF	CITATIONS
55	Intravesical capsaicin versus resiniferatoxin in patients with detrusor hyperreflexia: a prospective randomized study. Journal of Urology, 2002, 167, 1710-4.	0.2	21